26th February 2019
article written by
Cell Medica

Cell Medica Awarded USD 8.7 Million CPRIT Grant to Accelerate CMD-502 Off-the-shelf CAR-NKT Cell Therapy into Clinical Development

USD 8.7 million grant from CPRIT will support preclinical and clinical development of CMD-502 CMD-502 is an off-the-shelf chimeric antigen receptor-natural killer T cell (CAR-NKT) product that targets CD19 positive hematological malignancy Grant will also support preclinical development of additional off-the-shelf CAR-NKT products for various solid tumors Research and development to be conducted at Baylor […]

Read Full Article
20th September 2018
article written by
Cell Medica

First neuroblastoma patient successfully dosed with innovative CAR therapy utilizing natural killer T cells (CAR-NKT)

Ground-breaking Phase 1 trial, GINAKIT2, part of Cell Medica’s collaboration with Baylor College of Medicine and Texas Children’s Hospital Study is evaluating highly innovative CAR-NKT therapy, CMD-501, in children with high risk neuroblastoma NKT cell-based platform holds promise for CAR therapy in solid tumors and as a basis for future ‘off-the-shelf’ CAR therapy HOUSTON and […]

Read Full Article
1st August 2018
article written by
Cell Medica

Cell Medica Appoints New CEO to Drive CAR and TCR Clinical Development and Commercialisation

LONDON and HOUSTON – 1 August 2018 – Cell Medica (or ‘the Company’), a leader in the development, manufacture and marketing of personalised cellular immunotherapeutics for the treatment of cancer, has appointed Chris Nowers as Chief Executive Officer (CEO) and Executive Director. His appointment follows founder Gregg Sando’s decision to step down as Chief Executive […]

Read Full Article
1st August 2018
article written by
Cell Medica

Publication of ASPIRE Clinical Trial Results

Cell Medica Announces Publication of ASPIRE Clinical Trial Results All Patients Cleared Adenovirus Infection Following Cytovir ADV™ Treatment The results of the phase 1/2 ASPIRE study of adenovirus-specific T cells (Cytovir ADV) in pediatric patients after allogeneic hematopoietic stem cell transplantation (HSCT) have been published (Ip et al, Cytotherapy, 2018; 20:830-38).   In the ASPIRE study, […]

Read Full Article